Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
GP2GP likely to be phased out and more briefs
Te Whatu Ora plans to address risks of the outdated GP2GP electronic record system until a new digital health record launches midyear. In Western Australia,
